Core Points - On November 3, 2025, Zhongheng Group announced that its controlling shareholder, Guangxi Investment Group Co., Ltd. (referred to as "Guangxi Investment"), signed a capital increase agreement and share transfer agreement with Guangxi Investment Group Financial Holding Co., Ltd. (referred to as "Guangxi Financial Holding") [1] - Guangxi Investment will transfer 859,343,587 shares (26.89% of the total share capital) to Guangxi Financial Holding for a total consideration of RMB 4,070.536 million, equivalent to RMB 4.74 per share [1] - The transaction has been confirmed by the Shanghai Stock Exchange and the share transfer registration was completed on October 31, 2025, resulting in Guangxi Financial Holding becoming the new controlling shareholder of Zhongheng Group, while the actual controller remains the State-owned Assets Supervision and Administration Commission of the People's Government of Guangxi Zhuang Autonomous Region [1]

Core Points - On November 3, 2025, Laimei Pharmaceutical announced that its indirect controlling shareholder, Guangxi Investment Group Co., Ltd. (referred to as "Guangxi Investment Group"), signed an "Equity Increase Agreement" and "Share Transfer Agreement" with Guangxi Investment Group Financial Holding Co., Ltd. (referred to as "Guangxi Financial Holding") [1] - Guangxi Investment Group plans to increase capital by transferring 859,343,587 shares (26.89% of the total share capital) of its holding in the controlling shareholder, Guangxi Wuzhou Zhongheng Group Co., Ltd. (referred to as "Zhongheng Group"), to Guangxi Financial Holding [1] - The transfer has been confirmed for compliance by the Shanghai Stock Exchange and received a "Securities Transfer Registration Confirmation" from China Securities Depository and Clearing Co., Ltd. on November 3, 2025, with the transfer date being October 31, 2025 [1] - After the completion of the share transfer registration, Guangxi Financial Holding will become the indirect controlling shareholder of the company, while Zhongheng Group remains the direct controlling shareholder, and the actual controller of the company is still the State-owned Assets Supervision and Administration Commission of the People's Government of Guangxi Zhuang Autonomous Region [1]

Core Viewpoint - Guangxi Investment Group, the actual controller of Guohai Securities, signed an agreement with its subsidiary Guangtou Jinkong to increase capital by transferring 858 million shares of Zhongheng Group, representing 26.89% of the total share capital [1] Group 1 - As of the announcement date, Zhongheng Group and Guangtou Jinkong held 3.84% and 6.75% of Guohai Securities' shares, respectively [1] - On November 3, the relevant shares were successfully transferred, resulting in Guangtou Jinkong becoming the controlling shareholder of Zhongheng Group [1] - Following the adjustment, Guangtou Jinkong directly or indirectly holds 10.60% of Guohai Securities, maintaining its status as a major and second shareholder [1] Group 2 - The adjustment does not affect the actual controller and control rights of the company [1] - A portion of Zhongheng Group's shares will be locked until November 17, 2028 [1]

一、协议转让前期基本情况 重要内容提示： 2025 年 9 月 26 日，广西梧州中恒集团股份有限公司（以下简称"公司"或 "中恒集团"）的控股股东广西投资集团有限公司（以下简称"广投集团"）与 广西投资集团金融控股有限公司（以下简称"广投金控"）签署了《增资协议》 《股份转让协议》，广投集团以其所持有的公司 859,343,587 股（占公司总股本的 26.89%）无限售条件流通股股份对其控股公司广投金控进行增资扩股。广投集团 持有中恒集团股份数量为 859,343,587 股，增资总计作价人民币 407,053.60 万元 （折合每股人民币 4.74 元），其中 296,621.438461 万元计入广投金控注册资本， 110,432.161539 万元计入广投金控资本公积后，再向广投金控原股东等比例转增 资本。 本次协议转让事项已经上海证券交易所合规性确认，并于 2025 年 11 月 3 日 取得中国证券登记结算有限责任公司出具的《证券过户登记确认书》，过户日期 为 2025 年 10 月 31 日，过户数量为 859,343,587 股（占公司股份总数的 26.89%）， 股份性质为无限售条件流通股 ...

1 证券代码：600252 证券简称：中恒集团 公告编号：临 2025-90 广西梧州中恒集团股份有限公司 关于控股子公司参加第十一批全国药品集中采购 拟中选的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）的控 股子公司重庆莱美药业股份有限公司（以下简称"莱美药业"）参加了由国家组 织药品联合采购办公室（简称"联采办"）组织开展的第十一批全国药品集中采 购投标工作。根据联采办发布的《全国药品集中采购拟中选结果公示》，莱美药 业产品尼可地尔片拟中选本次集中采购，现将相关情况公告如下： 注：该产品的拟中选价格、拟中选数量及拟供应省区均以联采办发布的最终数据为准。 二、本次拟中选对公司的影响 莱美药业上述拟中选产品尼可地尔片（规格：5mg）于 2025 年 9 月取得国 家药品监督管理局核准签发的《药品注册证书》，具体内容详见公司于 2025 年 9 月 18 日在上海证券交易所网站披露的《广西梧州中恒集团股份有限公司关于 控股子公司获得药品注册证书的公告》（公告 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2025-89 广西梧州中恒集团股份有限公司 关于拟注销南宁中恒双钱实业有限公司的公告 本次注销事项不构成关联交易，也不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。根据《上海证券交易所股票上市规则》《公司章程》等相 关规定，公司本次注销事项在董事会审批权限范围内，无需提交股东大会审议。 具体情况如下： 一、拟注销主体基本情况 （一）基本情况 | 企业名称 | 南宁中恒双钱实业有限公司 | | --- | --- | | 统一社会信用代码 | 91450100340314655M | | 法定代表人 雷晓刚 | | | 类型 | 有限责任公司（非自然人投资或控股的法人独资） | | 成立日期 2015-6-9 | | | 注册资本 5,000.00 | 万元 | | 登记机关 | 南宁市市场监督管理局经济技术开发区分局 | | 住所 | 南宁市高岭路 号 号车间 100 1 | | 经营范围 | 食品的生产及销售（凭许可证在有效期内开展经营活动，具体项目以审 | | | 批部门批准的为准）；自营和代理一般经营项目商品和技术的进出口业 | | ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2025-88 广西梧州中恒集团股份有限公司 第十届董事会第三十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）第十 届董事会第三十二次会议通知和议案材料于 2025 年 10 月 24 日以电子邮件的方式 发出，会议于 2025 年 10 月 30 日以现场结合通讯方式在广西南宁市江南区高岭路 100 号办公楼会议室召开，公司董事长杨金海先生以现场方式出席并主持会议。 会议应当出席董事 8 人，实际出席会议董事 8 人，其中，董事王海润先生出席现 场，其他董事以通讯方式出席。会议的召集和召开符合《公司法》《公司章程》 和《公司董事会议事规则》的有关规定。 二、董事会会议审议情况 会议审议并以记名投票方式表决通过以下议案及事项： （一）会议审议通过《广西梧州中恒集团股份有限公司关于增补董事会专门 委员会成员的议案》； 根据《公司法》《公司章程》以及董事会各专门委员会议 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2025-91 广西梧州中恒集团股份有限公司 关于政府收储控股孙公司土地进展的更正公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、《关于政府收储控股孙公司土地的进展公告》（公告编号：临 2025-87） 更正前： 目前，肇庆高新区土储中心累计支付收储补偿价款及欠付款本金的利息共计 433,508,531.20 元，其尚欠肇庆中恒制药欠付款本金 388,000,000.00 元以及对应 期间内欠付款本金的利息。 更正后： 目前，肇庆高新区土储中心累计支付收储补偿价款及欠付款本金的利息共计 433,508,531.20 元，其尚欠肇庆中恒制药欠付款本金 391,000,000.00 元以及对应 1 期间内欠付款本金的利息。 广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）分别 于 2025 年 7 月 2 日、2025 年 10 月 10 日披露了《广西梧州中恒集团股份有限公 司关于政府收储控股孙公司土地的进展公告》（公告编号：临 2025-62、临 ...

Financial Performance - The company's operating revenue for the third quarter was ¥497,081,271.12, a decrease of 3.65% compared to the same period last year[4] - The total profit for the third quarter was -¥16,674,934.43, with a year-to-date profit of ¥11,059,706.30, reflecting a significant increase of 1,266.89% year-on-year[4] - The net profit attributable to shareholders for the third quarter was -¥2,437,249.27, while the year-to-date net profit was ¥24,640,374.94, an increase of 119.61% compared to the previous year[4] - The basic and diluted earnings per share for the third quarter were both -¥0.0008, while the year-to-date figures were ¥0.0078, showing a year-on-year increase of 136.36%[4] - Total operating revenue for the first three quarters of 2025 was CNY 1,809,411,026.87, down from CNY 2,401,872,835.33 in the same period of 2024, representing a decrease of approximately 24.6%[26] - The net profit attributable to shareholders of the parent company for the first three quarters of 2025 was CNY 24,640,374.94, compared to CNY 11,220,044.44 in 2024, showing an increase of approximately 119.5%[25] - The company reported a total profit of CNY 11,059,706.30 for the first three quarters of 2025, a significant increase from CNY 809,116.89 in the previous year[24] - The total comprehensive income for the first three quarters of 2025 was CNY 41,197,411.17, down from CNY 228,751,560.29 in 2024, indicating a decrease of about 82.0%[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥11,064,253,519.24, an increase of 0.78% from the end of the previous year[5] - The equity attributable to shareholders decreased to ¥5,799,508,176.13, down 3.71% from the previous year-end[5] - The company's total assets amounted to CNY 11,064,253,519.24, an increase from CNY 10,979,027,992.83 at the end of 2024[20] - Total liabilities as of September 30, 2025, were CNY 3,801,657,442.08, compared to CNY 3,464,282,597.71 at the end of 2024[21] - The company's equity attributable to shareholders was CNY 5,799,508,176.13, down from CNY 6,022,749,391.71 at the end of 2024[21] - Short-term borrowings increased to CNY 1,583,058,093.92 from CNY 1,304,042,585.63 year-over-year[21] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥156,396,673.89, reflecting a decrease of 135.05% compared to the same period last year[4] - Net cash flow from operating activities for the first three quarters of 2025 was -CNY 156,396,673.89, compared to CNY 446,258,897.73 in 2024, indicating a significant decline[26] - The cash and cash equivalents at the end of the period were CNY 4,009,475,304.33, up from CNY 3,458,763,556.53 in 2024, reflecting an increase of about 15.9%[27] - The company incurred a net cash outflow from investing activities of -CNY 23,674,555.79 in 2025, compared to a net inflow of CNY 613,984,380.89 in 2024[27] - The company’s total cash inflow from financing activities was CNY 1,584,881,111.98, compared to CNY 1,075,294,376.79 in 2024, marking an increase of approximately 47.3%[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 118,959[11] - Guangxi Investment Group Co., Ltd. holds 859,343,587 shares, accounting for 26.89% of total shares[11] - The company plans to repurchase shares at a price not exceeding RMB 3.80 per share, with a total repurchase amount between RMB 300 million and RMB 500 million[13] - As of August 25, 2025, the company completed the repurchase of 118,117,197 shares, representing 3.5649% of the total share capital, with a total expenditure of RMB 301,021,106.92[14] Product Development and Market Position - The company’s subsidiary received a total of RMB 10,365,548.61 in compensation from the Zhaoqing High-tech Zone Land Reserve Center during the first three quarters of 2025[16] - The company’s subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., received approval for a supplementary application for an injectable drug, enhancing its market competitiveness[17] - Guangxi Zhongheng Innovation Pharmaceutical Research Co., Ltd. acquired a patent for a drug technology for treating chronic heart failure for RMB 55 million[17] - The company received drug registration certificates for two products, Nicorandil tablets (5mg) and Ketorolac tromethamine injection (1ml:30mg), enhancing its product line[18] - The company plans to expand its product offerings and enhance its market presence through new drug registrations and technology transfers[18] Accounting Standards - The new accounting standards or interpretations will be implemented starting from 2025, affecting the financial statements from the beginning of that year[28]

Core Viewpoint - Zhongheng Group's subsidiary, Laimei Pharmaceutical, is participating in the 11th batch of national centralized drug procurement and aims to be selected for the procurement of Nicorandil tablets, which have not yet commenced sales [1] Group 1 - The potential selection for procurement could enhance product sales and market expansion for the company [1] - Successful procurement and contract signing would positively impact the company's brand influence and long-term development [1] - There are uncertainties regarding the bidding results and contract signing, and various factors affect drug production and sales [1]